Published in Medical Letter on the CDC and FDA, November 25th, 2007
Itamar Medical's ENDO-Pat device was the diagnostic tool used in this phase of the Framingham study, which found a link between endothelial dysfunction and cardiovascular risk factors including cholesterol, blood pressure and being overweight. In light of this latest scientific confirmation of PAT technology, Itamar Medical will now promote widespread clinical use of this approach for the prevention of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA